Literature DB >> 9335451

Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies.

M J Flens1, G L Scheffer, P van der Valk, H J Broxterman, E W Eijdems, A C Huysmans, M A Izquierdo, R J Scheper.   

Abstract

Since some multidrug-resistant (MDR) tumor cell lines show drug accumulation defects but do not over-express Pgp or MDR protein (MRP), a search was made for novel MDR-related transporter proteins by immunizing rats with non-small cell lung cancer SW- 1573/2R120 cells to produce monoclonal antibodies (MAbs). Five rat MAbs (LMR-4, -12, -42, -44 and -94) were generated, showing strong membranous staining of non-Pgp MDR SW- 1573/2R120 tumor cells and minimal reactivity to the corresponding parental and revertant cell lines. In addition, a 6th MAb (LMR-5) was isolated, recognizing the MDR-related lung resistance protein (LRP), previously identified as the major vault protein. The first 5 LMR MAbs show predominantly membranous staining of several non-Pgp MDR tumor cell lines of different histogenetic origins, except for LMR-4, which recognizes only MDR sublines of the SW- 1573 cell line. Flow-cytometric analysis revealed that all MAbs, except LMR-4 and -5, detect outside epitopes. Functional studies showed that these MAbs did not restore the daunorubicin accumulation defect. All but one of the MAbs (LMR-42) showed staining of distinct normal human tissues, notably epithelial cells lining the airways and digestive tract. In addition, staining of vascular endothelial cells was found with all MAbs except LMR-4. Three MAbs (LMR-12, -44 and -94) showed remarkable immunoreactivity with vincristine-selected SW- 1573 sublines. By immunoblotting and precipitation, the LMR antigens were found to be in the 42-69 kDa range.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9335451     DOI: 10.1002/(sici)1097-0215(19971009)73:2<249::aid-ijc15>3.0.co;2-a

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.

Authors:  G Musumarra; D F Condorelli; A S Costa; M Fichera
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues.

Authors:  A B Schroeijers; G L Scheffer; M J Flens; G A Meijer; M A Izquierdo; P van der Valk; R J Scheper
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  Multidrug resistance related molecules in human and murine lung.

Authors:  G L Scheffer; A C L M Pijnenborg; E F Smit; M Müller; D S Postma; W Timens; P van der Valk; E G E de Vries; R J Scheper
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

5.  Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein.

Authors:  G L Scheffer; A W Reurs; B Jutten; S H W Beiboer; R van Amerongen; M Schoester; E A C Wiemer; H R Hoogenboom; R J Scheper
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

6.  Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.

Authors:  G M Kolfschoten; T M Hulscher; H M Pinedo; E Boven
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

7.  Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Authors:  G L Scheffer; M C de Jong; A Monks; M J Flens; C D Hose; M A Izquierdo; R H Shoemaker; R J Scheper
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.